Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.
C. Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Pfizer
Honoraria - Wyeth
Research Funding - Wyeth
J. E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
D. Kim
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
H. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
N. Khattry
No relevant relationships to disclose
J. H. Lipton
No relevant relationships to disclose
C. Powell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
P. Harris
Employment or Leadership Position - Pfizer
A. M. Countouriotis
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
T. H. Brummendorf
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer